225 related articles for article (PubMed ID: 10459815)
21. Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa.
Ferretti C; Poma NV; Bernardo M; Rindi L; Cesta N; Tavanti A; Tascini C; Di Luca M
J Glob Antimicrob Resist; 2024 Jun; 37():53-61. PubMed ID: 38331031
[TBL] [Abstract][Full Text] [Related]
22. Imipenem antagonism of the in vitro activity of piperacillin against Pseudomonas aeruginosa.
Bertram MA; Young LS
Antimicrob Agents Chemother; 1984 Aug; 26(2):272-4. PubMed ID: 6435517
[TBL] [Abstract][Full Text] [Related]
23. Antibacterial activity of imipenem: the first thienamycin antibiotic.
Kropp H; Gerckens L; Sundelof JG; Kahan FM
Rev Infect Dis; 1985; 7 Suppl 3():S389-410. PubMed ID: 3931196
[TBL] [Abstract][Full Text] [Related]
24. Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing
Cojutti PG; Pai MP; Tonetti T; Siniscalchi A; Viale P; Pea F
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140423. PubMed ID: 38411995
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of BRL 36650, a new penicillin.
Van Landuyt HW; Lambert A; Boelaert J; Gordts B
Antimicrob Agents Chemother; 1986 Feb; 29(2):362-6. PubMed ID: 3087281
[TBL] [Abstract][Full Text] [Related]
26. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
[TBL] [Abstract][Full Text] [Related]
27. Combinations of antibiotics against Pseudomonas aeruginosa.
Baltch AL; Smith RP
Am J Med; 1985 Jul; 79(1A):8-16. PubMed ID: 3927722
[TBL] [Abstract][Full Text] [Related]
28. Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.
Johnson DE; Thompson B; Calia FM
Antimicrob Agents Chemother; 1985 Dec; 28(6):735-9. PubMed ID: 3909952
[TBL] [Abstract][Full Text] [Related]
29. Treatment Outcomes for Carbapenem-Resistant and Cephalosporin-Susceptible
Ng TH; Zhao JJ; Gumbleton R; Olson S; Smith S; Scipione MR
Ann Pharmacother; 2024 Jun; 58(6):581-588. PubMed ID: 37752788
[TBL] [Abstract][Full Text] [Related]
30. Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology.
López-Argüello S; Montaner M; Sayed AR; Oliver A; Bulitta JB; Moya B
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0160322. PubMed ID: 37199612
[TBL] [Abstract][Full Text] [Related]
31. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
Sime FB; Johnson A; Whalley S; Santoyo-Castelazo A; Montgomery AB; Walters KA; Lipman J; Hope WW; Roberts JA
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27795380
[TBL] [Abstract][Full Text] [Related]
32. Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.
Peterson LR; Gerding DN; Moody JA; Fasching CE
Antimicrob Agents Chemother; 1984 May; 25(5):545-52. PubMed ID: 6329087
[TBL] [Abstract][Full Text] [Related]
33. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
Bayer AS; Hirano L; Yih J
Antimicrob Agents Chemother; 1988 Feb; 32(2):231-5. PubMed ID: 3129985
[TBL] [Abstract][Full Text] [Related]
34. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.
Fung-Tomc J; Huczko E; Kolek B; Thater C; Kessler RE
Antimicrob Agents Chemother; 1991 Dec; 35(12):2652-4. PubMed ID: 1810203
[TBL] [Abstract][Full Text] [Related]
35. Imipenem-induced resistance to antipseudomonal beta-lactams in Pseudomonas aeruginosa.
Tausk F; Evans ME; Patterson LS; Federspiel CF; Stratton CW
Antimicrob Agents Chemother; 1985 Jul; 28(1):41-5. PubMed ID: 3929679
[TBL] [Abstract][Full Text] [Related]
36. Transcending the challenge of evolving resistance mechanisms in
Hujer AM; Marshall SH; Mack AR; Hujer KM; Bakthavatchalam YD; Umarkar K; Palwe SR; Takalkar S; Joshi PR; Shrivastava R; Periasamy H; Bhagwat SS; Patel MV; Veeraraghavan B; Bonomo RA
mBio; 2023 Oct; 14(6):e0111823. PubMed ID: 37889005
[TBL] [Abstract][Full Text] [Related]
37. Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.
Pfaller MA; Barry AL; Fuchs PC; Gerlach EH; Hardy DJ; McLaughlin JC
Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):728-32. PubMed ID: 1330566
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of E1040 against imipenem-resistant Pseudomonas aeruginosa strains.
Watanabe M; Inoue E; Katsu K; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1992 Mar; 36(3):684-6. PubMed ID: 1622186
[TBL] [Abstract][Full Text] [Related]
39. KPC-2-producing Pseudomonas aeruginosa isolated from wild animals in Brazil.
Dos Santos Costa J; Dos Santos PB; de Souza ATHI; Morgado TO; Cândido SL; Silva TRD; Nakazato L; Dutra V
Braz J Microbiol; 2023 Dec; 54(4):3307-3313. PubMed ID: 37819609
[TBL] [Abstract][Full Text] [Related]
40. Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae.
Moody JA; Fasching CE; Peterson LR; Gerding DN
Diagn Microbiol Infect Dis; 1987 Jan; 6(1):59-67. PubMed ID: 3100127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
